Ansari Mohammed Javeed I, Sayegh Mohamed H
Brigham & Women's Hospital, Boston, Massachusetts 02115, USA.
Kidney Int. 2004 May;65(5):1560-3. doi: 10.1111/j.1523-1755.2004.05411.x.
Organ transplantation is now well established as a preferred option for the treatment of end-stage organ failure. However, there is a severe shortage of donor organs and continued loss of a significant number of organ grafts due to chronic allograft dysfunction. Induction of tolerance of a transplant recipient toward their foreign organ graft, therefore, remains the "Holy Grail" of transplantation immunobiologists. Recently, clinical trials to explore pilot tolerance protocols in humans have been initiated. Defining the ideal strategy(ies) and the role of immunosuppressive drugs, developing tolerance assay(s), and enhancing cooperation between transplant professionals, industry, and the government are some of the challenges to achieving clinical transplantation tolerance. This article reviews the promise and the challenges of achieving clinical transplantation tolerance in human organ transplant recipients.
器官移植现已成为治疗终末期器官衰竭的首选方案。然而，供体器官严重短缺，且由于慢性移植器官功能障碍，大量移植器官持续丧失。因此，诱导移植受者对其异体器官移植产生耐受性仍然是移植免疫生物学家的“圣杯”。最近，已启动了在人体中探索试验性耐受方案的临床试验。确定理想的策略和免疫抑制药物的作用、开发耐受性检测方法以及加强移植专业人员、行业和政府之间的合作是实现临床移植耐受性面临的一些挑战。本文综述了在人体器官移植受者中实现临床移植耐受性的前景和挑战。
